



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 466 367 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91305837.6

(51) Int. Cl.⁵: C12Q 1/68

(22) Date of filing: 27.06.91

(30) Priority: 28.06.90 JP 170684/90

(43) Date of publication of application:
15.01.92 Bulletin 92/03

(84) Designated Contracting States:
CH DE FR GB IT LI NL

(71) Applicant: WAKUNAGA SEIYAKU KABUSHIKI
KAISHA
4-2-14, Fushimi-machi, Chuo-ku
Osaka-shi, Osaka-fu (JP)

(72) Inventor: Yamane, Akio, c/o Wakunaga
Seiyaku K.K.
1624, Shimo Koutachi, Kouda-Chō
Takata-Gun, Hiroshima-Ken (JP)

(74) Representative: Horton, Sophie Emma et al
Elkington and Fife, Prospect House, 8
Pembroke Road
Sevenoaks, Kent TN13 1XR (GB)

(54) Process for detecting nucleic acid.

(57) Single stranded nucleic acids which have a sequence that is complementary to a target nucleic acid sequence to be detected are immobilized on a solid support to place the single stranded nucleic acid under such a condition that a strand complementary to the single stranded nucleic acid is absent, and the immobilized single stranded nucleic acid is hybridized with a labelled target nucleic acid in a sample to detect the target nucleic acid.

A nucleic acid can be detected with a higher sensitivity when a single stranded nucleic acid containing a plurality of sequences hybridizable with the target nucleic acid is used as the single stranded nucleic acid to be immobilized.

EP 0 466 367 A1




FIG. 1

BACKGROUND OF THE INVENTIONField of the Invention

5 The present invention relates to a process for detecting a nucleic acid. More particularly, it is concerned with a process for detecting a target nucleic acid which enables a target nucleic acid to be rapidly detected and the detection procedure to be automated, which process comprises immobilizing single stranded nucleic acids which have a sequence that is complementary to a target nucleic acid sequence to be detected on a solid support and hybridizing the single stranded nucleic acid with a labelled target nucleic acid contained in a sample.

10 Description of the Related Art

Basic hybridization processes for detecting a specific sequence of a nucleic acid include a solid-liquid hybridization process wherein nucleic acids adsorbed on a solid support are hybridized with nucleic acids contained in a solution and a liquid-liquid hybridization process wherein target nucleic acids and nucleic acid probes contained in a solution are hybridized with each other (Anal. Biochem., 169, 1-25 (1988)). Up to now, these processes have been improved in various ways for the purpose of more easily, more rapidly and more sensitively detecting a target nucleic acid (Anal. Biochem., 169, 1-25 (1988)).

15 Among them, there is a proposal for a process wherein a microtiter well used in the field of immunoassay is utilized for automating the procedure of detecting a target nucleic acid (Japanese Patent Laid-Open Publication No. 219400/86). In this process, double stranded DNA in a sample are converted to a single stranded form, and the single stranded nucleic acids are immobilized through a nonspecific adsorption on a microtiter well under such a condition that complementary strands are present. Due to the inherent characteristics of DNA, some of the single stranded nucleic acids return to a double stranded form during the immobilization process and the subsequent hybridization process, so that in an actual hybridization, the amount of the hybridizable DNA appears to be substantially smaller than that of immobilized DNA. Further, in the immobilization process, the amount of DNA immobilized is relatively small which renders this process unsatisfactory from the practical viewpoint.

20 Immobilization of polythymidylic acids on a microtiter well has been proposed as a capturing probe for a sandwich hybridization process (Molecular and Cellular Probes, 3, 189-207 (1989)). This process is advantageous in that the amount of DNA immobilized is much larger than that in the case of a mixed base sequence of DNA by virtue of immobilization of a polymer of thymidylic acid having a higher reactivity than that of other nucleic acid bases in a photoreaction. The application of immobilized polythymidylic acids, however, is limited to a sandwich hybridization, with the disadvantages of complicated procedure and lower sensitivity inherent in the sandwich hybridization.

25 A nucleic acid amplification process called PCR (Polymerase Chain Reaction) was developed in recent years. It is the epoch-making process which can amplify a minute amount of a certain gene by one hundred thousand times or more in a short time (U.S. Patent No. 4,683,195). A proposal has been made for a process for detecting a mutation of human gene through the utilization of nucleic acids amplified by PCR (Proc. Natl. Acad. Sci., USA, 86, 6230-6234 (1989)). The proposed process is called "reverse dot hybridization" and characterized by chemically synthesized oligonucleotides complementary to a base sequence to be detected and adding polythymidylic acid to the oligonucleotides by an enzymatic reaction to facilitate the immobilization of the oligonucleotide on a nylon membrane. This process has the advantage of oligonucleotide being efficiently immobilized on a nylon membrane, but is disadvantageous in that the process wherein use is made of a nylon membrane, as such, is unsuitable for automation of the detection procedure and the preparation of the immobilized probes are unsuitable for mass production.

30 Although the above processes have advantages in some means, they have respective drawbacks and no process capable of realizing a satisfactory simpleness, rapidity and high sensitivity has been developed in the art.

50 SUMMARY OF THE INVENTION

The present inventors have found that a target nucleic acid can be simply and rapidly detected with high sensitivity through the use of a solid support wherein single stranded nucleic acids containing a sequence complementary to a target nucleic acid are immobilized to place the single stranded nucleic acid sequence in such a state that a strand complementary to the nucleic acid is absent, which has led to the completion of the present invention.

Accordingly, an object of the present invention is to provide a process capable of detecting a target nucleic

acid in a simple, rapid and highly sensitive manner.

Another object of the present invention is to provide a process for detecting a target nucleic acid which can easily be automated.

The process for detecting a nucleic acid comprises the following steps:

- 5 (i) labelling a target nucleic acid to be detected;
- (ii) immobilizing a single stranded nucleic acid specifically hybridizable with the target nucleic acid on an immobilization carrier to place said single stranded nucleic acid under such a condition that a strand complementary to said single stranded nucleic acid is absent;
- (iii) hybridizing said target nucleic acid labelled in step (i) with said single stranded nucleic acid immobilized in step (ii); and
- 10 (iv) detecting, simultaneously with or after the hybridization in step (iii), said target nucleic acid through the utilization of a label present in said target nucleic acid.

The process for detecting a nucleic acid according to the present invention enables a target nucleic acid to be specifically detected with high sensitivity and high efficiency and further enables the detection procedure 15 to be improved in the simplicess and rapidity and to be automated.

BRIEF DESCRIPTION OF THE DRAWINGS

The aforesaid and other objects and features of the present invention will now become apparent from the following detailed description with reference to the accompanying drawings, in which:

20 Fig. 1 is a flow diagram showing the construction of an improved vector for preparing a linear single stranded DNA and the preparation of the single stranded DNA;

Fig. 2 is a graph showing the results of a comparison of the hybridization efficiency on a single stranded DNA immobilized on a microtiter well with that on a double stranded DNA immobilized on a microtiter well;

25 Fig. 3 is a diagram showing nucleic acid sequences inserted into a vector for the preparation of an immobilized single stranded DNA in the detection of point mutation of β -thalassemia gene;

Fig. 4 is a flow diagram showing the preparation of a plasmid vector containing repetition of a oligonucleotide unit complementary to a human papilloma virus 16 gene;

Fig. 5 is a graph showing the relationship between the number of oligonucleotide units of an immobilized probe and the sensitivity; and

30 Fig. 6 is a diagram showing sequences of respective types of HLA-DB genes and a sequence of a probe used in the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Target Nucleic Acid

The term "target nucleic acid to be detected" used in the present invention is intended to mean a nucleic acid containing a specific base sequence to be detected and may be any of DNA and RNA. The nucleic acids to which the present invention is applicable can be prepared from every form of life including bacteria, virus and higher plants and animals. Further, when the detection process according to the present invention is applied, the nucleic acids may be in a purified form or in an unpurified form.

In the nucleic acid detection process according to the present invention, not only a nucleic acid obtained from the above-described form of life but also a synthesized nucleic acid corresponding to a nucleic acid derived from the specimen or a synthesized nucleic acid complementary to the nucleic acid may be used as the target nucleic acid to be detected. Therefore, in the present invention, the "target nucleic acid" includes besides a specimen-derived nucleic acid to be detected, a synthesized nucleic acid corresponding to the specimen-derived nucleic acid to be detected and further a synthesized nucleic acid complementary to the nucleic acid.

Nucleic Acid Detection Process

Step (i): Step of labelling target nucleic acid

In the nucleic acid detection process according to the present invention, a target nucleic acid to be detected is first labelled. Examples of the labelling method include (1) one wherein a label is directly introduced into a target nucleic acid, (2) one wherein a nucleic acid corresponding to the target nucleic acid or a nucleic acid complementary to the target nucleic acid is synthesized through the use of a labelled oligonucleotide primer and (3) one wherein a nucleic acid corresponding to the target nucleic acid or a nucleic acid complementary

to the target nucleic acid is synthesized through the use of an oligonucleotide primer in the presence of a labelled nucleotide unit.

5 A method wherein a biotin derivative is introduced into a target nucleic acid by a photoreaction and a detection is conducted by the use of enzyme conjugated streptoavidin (Nucleic Acids Res., 13, 745 (1985)) and a method wherein a target nucleic acid is sulfonated and detected by the use of an enzyme conjugated anti-sulfon antibody (Proc. Natl. Acad. Sci., USA, 81, 3466-3470 (1984)) are preferred as the method (1) wherein a label is directly introduced into a target nucleic acid from the viewpoints of simpleness and rapidity of the procedure.

An amplification of a specific nucleic acid sequence (BIO/TECHNOLOGY, 8, 291 (1990)) may be utilized for the methods (2) and (3). The methods have drawn attention particularly in respect of the amplification of a target nucleic acid and further are of a high value in relatively simple labelling of a synthesized nucleic acid corresponding to a target nucleic acid or a synthesized nucleic acid complementary to a target nucleic acid. For example, in the PCR process (Science, 230, 1350-1354 (1985)), a labelled elongation product or amplification product can be prepared through the utilization of a labelled primer or labelled mononucleotides. In the amplification method wherein use is made of Q β replicase (BIO/TECHNOLOGY, 6, 1197 (1988)), a labelled elongation product or amplification product can be prepared through the utilization of similarly labelled mononucleotides. Also in the nucleic acid amplification method other than described above, an elongation product or an amplification product can be labelled with labelled mononucleotides or labelled oligonucleotide incorporated by an elongation reaction or an amplification reaction. The method (2) is preferred in the present invention.

10 The label used herein may be radioactive or non-radioactive as far as this substance can be detected after the hybridization procedure. A non-radioactive label is preferred from the viewpoint of handleability, storage stability and disposal and because it can exhibit most efficiently the effect of the present invention.

15 Examples of the non-radioactive label include haptens, such as biotin, 2,4-dinitrophenyl group and digoxigenin, fluorescent substances such as fluorescein, rhodamine, tetramethylrhodamine, sulfo rhodamine, 7-nitrobenz-2-oxa-1,3-diazole (NBD) and dansyl group or chemiluminescent substances such as acridine. The 20 oligonucleotide can be labelled with the substance by any of the known means (Japanese Patent Laid-Open Publications No. 93098/84 and 93099/84). When labelled nucleotides are used, the labelling can be conducted by known means (Proc. Natl. Acad. Sci., USA, 80, 4045 (1983) and Japanese Patent Laid-Open Publication No. 152364/88). Alternatively, a commercially available product may be utilized.

30 Step (ii): Immobilization of single stranded nucleic acid

In the present step, single stranded nucleic acids specifically hybridizable with a target nucleic acid are immobilized on a solid support to place the immobilized single stranded nucleic acid under such a condition that a strand complementary to the single stranded nucleic acid is absent.

35 In the present invention, when the single stranded nucleic acid is DNA, it may be one prepared, for example, by denaturing a double stranded nucleic acid and subsequent strand separation (Nucleic Acids Res., 13, 5457-5468 (1985)). Further, it may be one prepared by synthesizing a single stranded nucleic acid through the use of a DNA polymerase and separating the synthesized single stranded nucleic acid from a template (Anal. Biochem., 162, 130-136 (1987)). Further, it is also possible to utilize a single stranded nucleic acid prepared from an M13 phage containing a gene to be detected, or a single stranded nucleic acid prepared from a composite vector comprising a phage and a plasmid (for example, pUC118, pBSM13+ and PUC11) (Methods in Enzymology, 153, 3-34 (1987)). When the single stranded nucleic acid is RNA, it may be not only a naturally occurring RNA but also RNA synthesized in vitro through the utilization of an RNA polymerase or the like. If a nucleic acid is inconvenient for the hybridization reaction, the inconvenient portion can be removed according to the Messing's method (Methods in Enzymology, 101, part C, 20 (1983)).

40 According to another aspect of the present invention, the single stranded nucleic acid to be immobilized is preferably one containing a plurality of sequences hybridizable with a target nucleic acid. This is because the presence of many sequences hybridizable with a target nucleic acid in a single stranded nucleic acid to be immobilized can shorten the time necessary for the hybridization, so that a gene can be rapidly detected.

45 Preferred examples of the single stranded nucleic acid containing a plurality of sequences hybridizable with a target nucleic acid include one prepared by introducing a plurality of sequences hybridizable with a target nucleic acid into the above-described phage DNA or a composite vector comprising a phage and a plasmid and preparing a single stranded nucleic acid therefrom. In particular, it is preferred to use a single stranded nucleic acid prepared from a vector containing 5 to 200 copies of a sequence hybridizable with a target nucleic acid.

50 When a point mutation or the like in a nucleic acid sequence in a sample is detected by hybridization, it is preferred that the sequence hybridizable with the target nucleic acid is relatively short.

In general, single stranded nucleic acids are immobilized on a solid support by the following method. In some cases, however, the immobilization efficiency is poor depending upon the immobilization method. Even in such a case, the immobilization through the use of single stranded nucleic acids containing a plurality of sequences hybridizable with a target nucleic acid is advantageous in that the sequence hybridizable with a target nucleic acid can be immobilized in a relatively large amount.

5 In general, it is known that the immobilization of the oligonucleotide comprising a sequence hybridizable with a target nucleic acid on a solid support causes the portion participating in the immobilization on the support to lose its degree of freedom and consequently to become impossible for it to participate in the hybridization. Thus, the hybridization efficiency of the immobilized oligonucleotides is lower than that attained in the solution.

10 When use is made of single stranded nucleic acids prepared through the use of the above-described vector containing a plural number of a unit sequence hybridizable with a target nucleic acid for the preparation of single strand DNA, however, a number of the unit sequence not involved in the immobilization on a solid support appear to be present. Thus, the lowering in the hybridization efficiency derived from the immobilization is advantageously small.

15 However, when the labelling is conducted through the use of an elongation reaction or an amplification reaction and the labelled product to be detected, the single stranded nucleic acid to be immobilized is preferably less homologous to primers utilized for the elongation reaction or amplification reaction. For example, in the PCR process, in many cases, the primer used in the gene amplification remains in the solution after the amplification reaction. In this case, it is necessary to select the sequence of the single stranded nucleic acid in such a manner that the primers do not hybridize with the single stranded nucleic acid. This is true of the other gene amplification methods.

20 The support for immobilizing the single stranded nucleic acid may be any material or any shape as long as a nucleic acid can be nonspecifically adsorbed, or a functional group can be introduced and a covalent bond can be formed between the functional group and the nucleic acid. Specific examples of the carrier include polymer microtiter well, tube and bead. The use of the microtiter well is particularly preferred from the viewpoint 25 of ease of automation of the procedure.

25 One of the methods of immobilizing single stranded nucleic acids on a solid support is a chemical binding method (e.g. Nucleic Acids Res., 15, 5373-5390 (1987)). Examples of the method of immobilizing the nucleic acid through a chemical bond include one wherein a carrier containing an amino group introduced thereto is bound to a nucleic acid through the use of a crosslinking agent such as glutaraldehyde. Further, the introduction 30 of a functional group (for example, a primary amino group through a transamination reaction) into a nucleic acid followed by binding of the introduced functional group onto a solid support through the use of a suitable crosslinking agent is also useful.

35 It is also possible to directly immobilize a nucleic acid onto a solid support through a nonspecific binding such as adsorption. In particular, when the support is a microtiter well, the adsorption efficiency can be enhanced through an ultraviolet irradiation or the addition of MgCl₂ (Japanese Patent Laid-Open Publication No. 219400/86). A further useful method is that in which a nucleic acid and a protein are chemically conjugated or 40 nonspecifically adsorbed to each other and the immobilization is conducted by taking advantage of a nonspecific adsorption of the protein to a carrier.

40 Thus, the immobilization of the fully hybridizable single stranded nucleic acids on a solid support can be achieved.

Step (iii): Hybridization step

45 In this step, the target nucleic acid labelled in step (i) is hybridized with the single stranded nucleic acid immobilized in step (ii).

The hybridization conditions may be properly selected and determined according to a combination of the target nucleic acid with the immobilized single stranded nucleic acid. For example, the hybridization in the present step can be basically conducted in the same manner as that wherein use is made of the conventional membranes (B.D. Hames and S.J. Higgins, Nucleic Acid Hybridization, A Practical Approach, IRL Press (1985)).

50 In some solid supports, the nonspecific adsorption to the nucleic acid becomes weak depending upon what hybridization conditions are used. In such a case, the procedure of the prehybridization reaction can be omitted. For the same reason, the composition of the solution can be simplified. When the hybridization reaction is conducted for a long period of time, the immobilized single stranded nucleic acids may often be liberated. Thus, it is preferred to conduct the hybridization under such conditions that the hybridization time can be reduced.

55 The washing procedure after the hybridization reaction as well can be conducted in the same manner as that of the conventional process. Because of simplicity, it is preferred to conduct the washing procedure under such conditions that excess reagents etc. can be removed at room temperature.

In the detection of a point mutation, the washing conditions should be carefully determined. It is also useful to utilize such conditions wherein the stability of duplex depends upon only the length of the complementary strand but does not depend upon the base composition of the complementary strand (Nucleic Acids Res., 16, 4637-4650 (1988)).

5

Step (iv): Step of detection

In this step, simultaneously with or after step (iii), a target nucleic acid is detected through the utilization of a label present in the target nucleic acid.

10

The detection procedure in the present step may be properly selected and determined according to the kind of the label present in the target nucleic acid.

15

When the label present in the target nucleic acid is directly detectable, that is, when the label is, for example, a radioisotope, a fluorescent substance or a dye, the detection procedure may be conducted in such a state that a labelled nucleic acid is bonded to a solid phase, or alternatively the detection procedure may be conducted by liberating the label into a solution in such a state that it is bonded to the nucleic acid or released from the nucleic acid and then conducting the detection according to the label. On the other hand, when the label is indirectly detectable, that is, when the label is a ligand capable of causing a specific binding reaction, such as biotin or hapten, the detection procedure can be conducted by a method commonly used in the detection of this type, that is, through the use of an acceptor (for example, avidin or antibody) to which a label capable of directly generating a signal or an enzyme catalyzing a signal generating reaction has been bound. The acceptor may be previously added in step (iii). In this case, the binding process of the ligand to the acceptor can be conducted simultaneously with step (iii) which results in the whole process being simplified.

20

EXAMPLES

25

The present invention will now be described in more detail by way of the following examples, though it is not limited to these examples only.

30

The procedure of the genetic engineering techniques in the following examples was conducted according to Molecular Cloning, the 2nd edition (T. Maniatis et al., Cold Spring Harbar Laboratory Press (1989)). Oligonucleotide was prepared through the use of a model 381 A automatic synthesizer manufactured by Applied Biosystems, Inc. and subjected to deprotection reaction and purification before use by the conventional procedure (Oligonucleotide Synthesis, IRL Press (1984)). The biotin-labelled oligonucleotide was prepared by adding Aminolink II (trademark) (manufactured by Applied Biosystems, Inc.) to oligonucleotide in the final stage of the synthesis of the oligonucleotide to introduce an amino group into the oligonucleotide, and reacting the oligonucleotide with biotin succinimide ester according to the method described in U.S. Patent No. 4,849,336.

35

Example 1

Preparation of single stranded DNA for immobilization

40

In order to prepare a linear single stranded DNA, use was made of a modification of a method by Messing et al. (Methods in Enzymology, 101, Part C, 20 (1983)). A chemically synthesized DNA fragment shown in Fig. 1 was inserted in between EcoRI cleaved site and Hind III cleaved site of plasmid pBSM13+ (manufactured by Stratagene Cloning Systems, Inc.) to prepare plasmid pUPPO1. Then, a 1.8 kb fragment containing genes E6 and E7 of human papilloma virus 16 was inserted into a Hinc 11 cleaved site of this plasmid to prepare plasmid pUPPHP16. *E. coli* NM522 was transformed with the plasmid, and a single stranded DNA was prepared by the conventional procedure through the use of helper phage M13K07 (Methods in Enzymology, 153, 3-34 (1987)). The single stranded DNA was cleaved by restriction enzyme EcoRI or BamHI for linearization.

45

Example 2

Immobilization of single stranded DNA on microtiter well

The single stranded DNA prepared in Example 1 was dissolved in a solution of 10 mM Tris-HCl, pH 7.6, and 1 mM EDTA to a concentration of 100 ng/ μ l and then mixed with a four-fold volume of H₂O and a five-fold volume of an immobilization buffer (1.5 M NaCl, 0.3 M Tris-HCl, pH 8.0, 0.3 M MgCl₂). The mixture was added to a microtiter well (Dynatech, Immulon 2, removawell strips, No. 011-010-6302) in an amount of 100 μ l per well. The well was covered and allowed to stand at 37°C for 16 hr. Then, the liquid was removed, and the well

was air-dried at 37°C for 30 min and subjected to light irradiation at a dose of 500,000 µJ through the use of Stratalinker (trademark) 2400 (manufactured by Stratagene Cloning Systems, Inc.). After the light irradiation, the well was washed three times with a washing buffer (1 M NaCl, 2 mM MgCl₂, 0.1 M Tris-HCl, pH 9.3, 0.1% Tween 20 : 200 µl). The well was then sealed in a polyvinyl chloride bag and stored at 4°C.

5

Example 3

Hybridization in microtiter well and detection

10 A hybridization solution (5 x SSC, 5 x Denhardt's solution, 0.2% SDS, 200 µg/ml, salmon sperm DNA: 100 µl/well) was added to the well on which the single stranded DNA containing a human papilloma virus 16 gene prepared in Example 2 had been immobilized, and further a serial dilution of biotin-labelled oligonucleotides (Bio-ATTGTAATGGGCTCTGTCCG, 20 ng/well) complementary to part of the human papilloma virus 16 gene was added thereto. The mixture was maintained at 55°C for 30 min. The hybridization solution was removed, 15 and the well was washed three times with 2 x SSC (200 µl/well). A streptoavidin-alkaline phosphatase solution (prepared by subjecting a solution of streptavidin-alkaline phosphatase (Bethesda Research Laboratories, Inc.) to 1,000-fold dilution with 0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 2 mM MgCl₂, 0.05% (v/v) Triton X-100) was added to the thereto (100 µl/well), and the well was shaken at 23°C for 10 min. The reaction mixture was removed from the well, and the well was washed three times with a washing solution (0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 2 mM 20 MgCl₂, 0.05% (v/v) Triton X-100: 200 µl/well). After the washing, a p-nitrophenyl phosphate solution (1 M diethanolamine, pH 9.8, 0.5 mM MgCl₂: 4 mg/ml; 100 µl/well) was added to the well and a reaction was allowed to proceed at 23°C for one hr. Absorbance was then measured at 405 nm. The results are given in Table 1.

Table 1

| | Absorbance (at 405 nm) |
|---|------------------------|
| Plate on which single stranded DNA containing a human papilloma virus sequence has been immobilized | 1.34 |
| Plate on which single stranded DNA unrelated a human papilloma virus sequence has been immobilized | 0.13 |
| Plate on which no DNA has been immobilized | 0.13 |

The numerical value in Table 1 is one determined from the absorbance at 405 nm by subtracting the background value derived from the substrate itself.

Example 4

Effect of UV irradiation on immobilization of DNA on microtiter well

50 The plasmid DNA (pUPPHP16) prepared in Example 1 and single stranded DNA prepared therefrom were linearized by cleaving with EcoRI and immobilized on a plate in the same manner as that of Example 2. In this case, when double stranded DNA was immobilized, heat denaturation was conducted before the double stranded DNA was mixed with the immobilization buffer. Then, two types of plates were prepared. Specifically, in one plate, UV irradiation was conducted in the same manner as that of Example 2, and in another plate, no UV irradiation was conducted. The hybridization capability of the plates thus prepared was examined through the use of Bio-ATTGTAATGGGCTCTGTCCG in the same manner as that of Example 3. The results are given in Table 2.

Table 2

| | UV irradiation | No UV irradiation |
|---------------------|----------------|-------------------|
| Double stranded DNA | 0.51 | 0.48 |
| Single stranded DNA | 1.58 | 0.58 |

The numerical value in Table 2 was determined from the absorbance at 405 nm by subtracting the background value derived from the substrate itself.

Example 5

Comparison of hybridization capability after immobilization on plate of single stranded DNA with that of double stranded DNA

The hybridization capability after immobilization on a plate of single stranded DNA was compared with the hybridization capability after immobilization on a plate of denatured double stranded DNA. The single stranded DNA and the double stranded DNA were prepared in substantially the same manner as that of Example 4. The single stranded DNA were immobilized in a cyclic form.

DNA was added in an amount of 1 µg, 100 ng and 10 ng each per well for immobilization in the same manner as that of Example 2. The hybridization capability of each plate was examined through the use of Bio-ATTG-TAATGGGCTCTGTCCG as a probe in the same manner as that of Example 3. The results were as shown in Fig. 2 (the absorbance at 405 nm was measured by a microplate reader).

Example 6

Labelling by gene amplification and detection of amplification product and detection of point mutation

In order to detect a human β-globin gene, an oligonucleotide corresponding to the 2nd to 11th codons was chemically synthesized and inserted into a *Hinc*II site of plasmid pUC11 (see Fig. 3). The procedure was conducted for both a normal gene (βA) and a point mutated gene (βS) causative of β-thalassemia. Among the resultant clones, a clone capable of providing a sense single stranded DNA was selected, and single stranded DNA was prepared therefrom. The single stranded DNA thus prepared were immobilized in a cyclic form on a plate according to the procedure described in Example 2.

Then, a gene amplification reaction was conducted. The reaction was conducted through the use of GeneAmp (trademark) manufactured by Cetus Corporation according to the protocol. 5' ACACAACTGTGTGTTCACTAGC and biotinylated Bio-CAACTTCATCCACGTTCAACC were used as the primer, and 4.4 kb DNA fragments prepared from the plasmid DNA (pBR322-H_PPst) by the digestion of Pst I (DNA, 3, 7-15 (1984)) was used as the template.

After the gene amplification, an aliquot of the reaction mixture was heat-denatured and subjected to hybridization and subsequent detection in the same manner as that of Example 3. The results are given in Table 3 (the measurements are those determined by a microplate reader).

Table 3

| | Absorbance (at 405 nm) |
|---|------------------------|
| Plate on which DNA containing β A sequence has been immobilized | 0.432 |
| Plate on which DNA containing β S sequence has been immobilized | 0.288 |
| Plate on which DNA unrelating to β -globin has been immobilized | 0.037 |

20 Example 7

Preparation of single stranded DNA containing repetition of unit sequence

A part of E7 gene of human papilloma virus 16 was chemically synthesized, and single stranded DNA containing repetition of a sequence of the synthesized oligonucleotides (the unit sequence) was prepared therefrom according to the method shown in Fig. 4.

29 according to the method shown in Fig. 4.

At the outset, two kinds of oligonucleotides shown in Fig. 4 were chemically synthesized, and the 5' terminal
 thereof was phosphorylated with polynucleotide kinase and ATP. Then, the two kinds of oligonucleotides were
 mixed with each other to form a double strand. The fragments of the double strand were linked to each other
 through the use of T4 DNA ligase. After ligation, blunt ends were formed through the use of Klenow fragment
 of *E. coli* DNA polymerase and four kinds of deoxynucleoside triphosphates. The resultant reaction product was
 electrophoresed on 6% polyacrylamide gel, and a portion corresponding to 270 bp was cut out to recover DNA.
 30 *In vitro* endonuclease (kindly supplied by Dr. H. Itoh, Open Publication No. 190194/90) was cleaved by a res-

Then, plasmid pUC-Sfix2 (Japanese Patent Laid-Open Publication No. 190194/90) was cleaved by a restriction enzyme BamHI, and the terminal 5' phosphate was removed with alkaline phosphatase. This product was ligated with T4 DNA ligase to the DNA recovered from the polyacrylamide gel. *E. coli* JM109 was transformed with the ligated product. An intended clone was selected for resistibility of ampicillin. The plasmid pUC-Sfi27x thus obtained was cleaved by restriction enzyme SfiI, and a portion containing repetition of the unit sequence was purified and recovered through the use of electrophoresis. This fragment was self-ligated with T4 DNA ligase and inserted into a restriction enzyme SfiI site of plasmid pUC119S (prepared by inserting SfiI linker (manufactured by Boehringer Mannheim; #909785) into a BamHI cleaved site of pUC119). Clones are different from each other in the number of the unit sequence depending upon the degree of self-ligation. In the present experiment, clones wherein the numbers of the unit sequence is 9, 14, 64 and 165 were obtained.

Example 8

Effect of probe into which oligonucleotide has been repeatedly inserted

Single stranded DNAs were prepared respectively from the clone prepared in Example 7 and a separately prepared clone having one unit sequence in the same manner as that of Example 1 and immobilized on a micro-titer well in the same manner as that of Example 2.

Then, the following gene amplification was conducted through the use of the following two biotin-labelled primers:

Bio-GCAACCAGAGACAACGTGATC
Bio-ATTGTAATGGGCTCTGTCCG

plasmid containing a E7 gene of papilloma virus 16 (HPV16) as a template.

and a plasmid containing a E7 gene of papilloma virus 16 (HPV16) as a template.

GeneAmp (trademark) reagent manufactured by Cetus Corporation was added to 10 ng of plasmid pUPPHP16 (see Example 1) and 100 ng of each primer according to the protocol, and the total volume of the reaction solution was adjusted to 100 μ l with water. The reaction solution was heated at 95°C for 5 min in a

thermal cycler manufactured by Perkin-Elmer Cetus Instruments, Inc. to denature DNA, and 2.5 units of AmpliTaq (trademark) was added thereto. The cycle of heating at 72°C for 60 sec, at 94°C for 30 sec and at 50°C for 30 sec was repeated 30 times.

The reaction mixture was diluted with water and 5 µl of the diluent was heat-denatured and hybridized with 5 a previously prepared microtiter well on which the single stranded DNA containing a E7 gene sequences has been immobilized under the same conditions as those described in Example 3, and the absorbance was measured.

10 The results are shown in Fig. 5. As is apparent from the drawing, when the number of the unit sequence was 64 or 165, the sensitivity was about 20 times that in the case where the number of the unit sequence was one.

Example 9

Detection of human papilloma virus 16 gene in rapid and simple manner

15 In order to simplify the hybridization process of the present invention further, studies were conducted on the composition of the hybridization solution, hybridization temperature and color development time, and the detection of a human papilloma virus 16 gene was conducted under the following simplified conditions.

20 10 ng of DNA extracted from Caski cells as a positive sample and 10 ng of DNA extracted from human peripheral blood as a negative sample were each used as a template, and gene amplification was conducted by the PCR process in the same manner as that of Example 8. The resultant reaction mixtures were added to wells prepared as in Example 8. On one well single stranded DNA wherein the number of repetitions of the unit sequence was one had been immobilized, and on the other well, single stranded DNA wherein the number of repetitions of the unit sequence was 64 had been immobilized. Hybridization was conducted in 100 µl of a hybridization solution (5 x SSC, 0.2% SDS) with 5 µl of the above-described PCR mixture at 37°C for 30 min. The hybridization solution was then removed from the well, and the well was washed three times with 200 µl of a washing solution (2 x SSC).

25 A streptoavidin-alkaline phosphatase solution (prepared by subjecting a solution of streptoavidinalkaline phosphatase (manufactured by Bethesda Research Laboratories, Inc.) to 1,000-fold dilution with 0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 2 mM MgCl₂, 0.05% (v/v) Triton X-100) was added thereto 100 µl/well, and the plate was gently shaken at 23°C for 10 min. The solution was removed from the well, and the well was washed three times with a washing solution (0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 2 mM MgCl₂, 0.05% (v/v) Triton X-100: 200 µl/well). After the washing, 100 µl of p-nitrophenyl phosphate solution (1 M diethanolamine, pH 9.8, 0.5 mM MgCl₂: 4 mg/ml) was added to the well and an enzymatic reaction was allowed to proceed at 23°C for 20 min.

30 35 The absorbance was then measured at 405 nm. The results are given in Table 4. As is apparent from Table 4, even when the procedure was simplified, the positive sample could be significantly distinguished from the negative sample in the case of single stranded DNA wherein the number of the unit sequence was 64.

40

45

50

55

Table 4

| Plate sample | Number of the unit sequence is 1 | Number of the unit sequence is 64 |
|--|----------------------------------|-----------------------------------|
| Positive sample (derived from Caski cells) | 0.04 | 0.73 |
| Negative sample (derived from normal human) | 0.00 | 0.02 |

Note: * The numerical value in Table 4 is one determined from the absorbance at 405 nm by subtracting the background value derived from the substrate itself.

Example 10Detection of mutation of HLA-DRB gene

Gene amplification was conducted through the use of the following two kinds of biotin-labelled primers [GLPDRB1: corresponding to the 17th to 23rd amino acids of HLA-DRB, GAMPDRB1: corresponding to the 87th to 94th amino acids of HLA-DRB, J. Exp. Med., 169, 2263-2267 (1989)]:

Bio-TTCTTCAATGGGACGGAGCG
Bio-GCCGCTGCACTGTGAAGCTCTC

and 1 µg of DNA extracted from human peripheral blood as a template in the same manner as that of Example 8. Unit sequences as shown in Fig. 6 (probe 1, 2, and 3) were repeatedly ligated in the same manner as that of Example 7 and immobilized on a well, respectively. Probe 1 is completely matched to a gene sequence of genotype DR4, while probe 2 is completely matched to a gene sequence of genotypes DR4/DW 10 and DRW 13 (see Fig. 6). Probe 3 is complementary to a common sequence of all the genotypes. In probes 1 and 2, the number of the unit sequence was 50, while in probe 3, the number of the unit sequence was 10.

The gene amplification reaction cycle of heating at 94°C for 30 sec, at 50°C for 30 sec and at 72°C for 60 sec was repeated 30 times. 5 µl of the reaction mixture was added to wells on which probes 1, probe 2 and probe 3 had been immobilized, and the hybridization was conducted at 60°C for one hr and the enzymatic reaction was conducted at 23°C for one hr. Other detailed procedure was as same as that of Example 3.

The results are given in Table 5. Both wells on which probe 1 and probe 2 were immobilized exhibited a high absorbance specifically with genotypes expecting to have a high homology in the sequence. These results demonstrated that the present invention is useful for the typing of the HLA gene.

Table 5

| Sample Genotype | Probe 1 | Probe 2 | Probe 3 |
|---------------------|---------|---------|---------|
| 1 DR4/DW 15, DR9 | 7.5* | 0.12 | 10.1* |
| 2 DR4/DW 15 | 13.7* | 0.18 | 9.0* |
| 3 DRW 13, DRW 14 | 0.35 | 6.6* | 17.8* |
| 4 DR9, DRW 13 | 1.5 | 1.5* | 10.0* |
| 5 DRW 8/DW 8.3, DR9 | 6.9 | 0.17 | 12.1* |
| 6 DRW 14 | 0.37 | 0.19 | 18.0* |
| 7 DR2 | 0.67 | 0.10 | 15.3* |

Note: * Asterisk (*) in Table 5 is estimated that the probe is completely matched to the gene sequence of the genotype.

** The numerical value in Table 5 is one determined from the absorbance at 405 nm by subjecting the background value derived from the subsequent itself. When the absorbances were beyond two, the value obtained here was converted from that of a diluted solution.

35

40

45

50

55

Sequence Listing

SEQ ID NO: 1

SEQUENCE LENGTH: 20 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid. synthesized DNA

FEATURES

having biotin at 5' end with a spacer

SEQUENCE DESCRIPTION:

ATTGTAATGG GCTCTGTCCG

20

SEQ ID NO: 2

SEQUENCE LENGTH: 22 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid. synthesized DNA

SEQUENCE DESCRIPTION:

ACACAACTGT GTGTTCACTA GC

22

SEQ ID NO: 3

SEQUENCE LENGTH: 20 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid. synthesized DNA

FEATURES

having biotin at 5' end with a spacer

5

SEQUENCE DESCRIPTION:

10

CAACTTCATC CACGTTCA

20

SEQ ID NO: 4

15

SEQUENCE LENGTH: 20 base pairs

SEQUENCE TYPE: Nucleic acid

20

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid, synthesized DNA

25

FEATURES

having biotin at 5' end with a spacer

30

SEQUENCE DESCRIPTION:

35

GCAACCAGCG ACAACTGATC

20

SEQ ID NO: 5

40

SEQUENCE LENGTH: 20 base pairs

SEQUENCE TYPE: Nucleic acid

45

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid, synthesized DNA

50

FEATURES
having biotin at 5' end with a spacer

55

SEQUENCE DESCRIPTION:

TTCTTCAATG GGACGGAGCG

20

SEQ ID NO: 6

SEQUENCE LENGTH: 22 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid, synthesized DNA

FEATURES

having biotin at 5' end with a spacer

SEQUENCE DESCRIPTION:

GCCGCTGCAC TGTGAAGCTCC TC

22

SEQ ID NO: 7

SEQUENCE LENGTH: 40 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid, synthesized DNA

SEQUENCE DESCRIPTION:

CAGCTGAATT CGGATCCGTC GACGGATCCG AATTCAAGCTG

40

SEQ ID NO: 8

SEQUENCE LENGTH: 30 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid, synthesized DNA

SEQUENCE DESCRIPTION:

CACCTGACTC CTGAGGAGAA GTCTGCCGTT

30

5

SEQ ID NO: 9

10

SEQUENCE LENGTH: 30 base pairs

15

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid, synthesized DNA

20

SEQUENCE DESCRIPTION:

CACCTGACTC CTGTGGAGAA GTCTGCCGTT

30

25

SEQ ID NO: 10

30

SEQUENCE LENGTH: 27 base pairs

35

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: liner

MOLECULE TYPE: other nucleic acid, synthesized DNA

40

SEQUENCE DESCRIPTION:

AGGTATGAGC AATTAAATGA CAGCTCA

27

45

50

55

SEQ ID NO: 11

SEQUENCE LENGTH: 27 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid, synthesized DNA

SEQUENCE DESCRIPTION:

ACCTTGAGCT GTCATTTAAT TGCTCAT

27

20

SEQ ID NO: 12

SEQUENCE LENGTH: 300 base pairs

25

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

30

TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

ORIGINAL SOURCE

35

ORGANISM: human (*Homo sapiens*)

FEATURES

a part of human leukocyto antigen (HLA) DR gene

40

SEQUENCE DESCRIPTION:

| | | |
|----|--|-----|
| 45 | GGGGACACCC GACCACGTTT CTTGTGGCAG CTTAAGTTG AATGTCATT CTTCAATGGG | 60 |
| | ACCGGACCGGG TGGGGTTGCT CGAAACATGC ATCTATAACC AAGAGGGAGTC CGTGCCTTC | 120 |
| | GACACCGACG TGGGGGAGTA CCGGGCGGTG ACGGACCTGG CGCGGCCTGA TGCCGAGTAC | 180 |
| 50 | TGGAACAGCC AGAAGGACCT CCTGGAGCAG AGGCGGGCCG CGGTGGACAC CTACTGCAGA | 240 |
| | CACAACTAGC GGGTTGGTCA GAGCTTCACA GTCCAGCGGC CAGTTGAGCC TAAGGTGACT | 300 |

55

SEQUENCE DESCRIPTION:

| | | |
|----|--|-----|
| 5 | GGGGACACCC GACCACGTTT CTTGGAGCAG GTAAACATG AGTGTCAATT CTTCAACGGC | 60 |
| | ACGGAGCGGG TGCGGTTCCCT GGACAGATAAC TTCTATCACC AAGAGGAGTA CGTCCGCCTTC | 120 |
| | GACAGCGACG TGGGGGAGTA CCGGGCGGTG ACGGAGCTGG CGCGGCCTGA TGCCGAGTAC | 180 |
| 10 | TGGAACAGCC AGAAGGACAT CCTGGAAGAC GACCGGGCCCG CGGTGGACAC CTACTGCAGA | 240 |
| | CACAACTAGC GGCTTGTGGA GAGCTTCACA GTGCAGCGGC GANNNNNNNN NNNNNNNNN | 300 |

15 SEQ ID NO: 15

SEQUENCE LENGTH: 300 base pairs

20 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

25 MOLECULE TYPE: Genomic DNA

ORIGINAL SOURCE

30 ORGANISM: human (*Homo sapiens*)

FEATURES

35 a part of human leukocyto antigen (HLA) DR gene

SEQUENCE DESCRIPTION:

| | | |
|----|--|-----|
| 40 | GGGGACACCA GACCACGTTT CTGGAGTAC TCTACGTCTG AGTGTCAATT CTTCAATGGC | 60 |
| | ACGGAGCGGG TGCGGTTCCCT GGACAGATAAC TTCCATAACC AGGAGGAGAA CGTCCGCCTTC | 120 |
| | GACAGCGACG TGGGGGAGTT CCGGGCGGTG ACGGAGCTGG CGCGGCCTGA TGCCGAGTAC | 180 |
| 45 | TGGAACAGCC AGAAGGACAT CCTGGAAGAC GACCGGGCCCG CGGTGGACAC CTACTGCAGA | |
| | CACAACTAGC GGCTTGTGGA GAGCTTCACA GTGCAGCGGC GACTCCATCC TAAGGTGACT | |

50

55

SEQ ID NO: 13

5 SEQUENCE LENGTH: 300 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

10 TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

15 ORIGINAL SOURCE

15 ORGANISM: human (Homo sapiens)

FEATURES

20 a part of human leukocyto antigen (HLA) DR gene

SEQUENCE DESCRIPTION:

| | | |
|----|--|-----|
| 25 | GGGGACACCC GACCACGTTT CTTGGAGCAG GTAAACATG AGTGTCAATT CTCAACGGG | 60 |
| | ACGGAGCGGG TCGGGTTCCT GGACAGATACTTCTATCACC AAGAGGGAGTA CGTGCGCTTC | 120 |
| 30 | GACAGCGACG TGGGGGAGTA CCAGGGCGGTG ACAGGACCTGG CGCGGCCCTGA TGCCGAGTAC | 180 |
| | TGGAACACCC AGAAGGACCT CCTGGAGCAG AAGCGGGCCCG CGGTGGACAC CTACTGCAGA | 240 |
| | CACAACTAGG GGGTTGGTGA GAGCTTCACA GTGCAGCGGC GAGTCTATCC TGAGGTGACT | 300 |

35

SEQ ID NO: 14

40 SEQUENCE LENGTH: 300 base pairs

SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: double

45 TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

ORIGINAL SOURCE

50 ORGANISM: human (Homo sapiens)

FEATURES

55 a part of human leukocyto antigen (HLA) DR gene

SEQ ID NO: 16

SEQUENCE LENGTH: 20 base pairs

5 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

10 MOLECULE TYPE: other nucleic acid, synthesized DNA

15 SEQUENCE DESCRIPTION:

TACTTCTATC ACCAAGAGAA

20

20 SEQ ID NO: 17

SEQUENCE LENGTH: 18 base pairs

25 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

30 MOLECULE TYPE: other nucleic acid, synthesized DNA

35 SEQUENCE DESCRIPTION:

GAAGACGAGC GGGCCGCG

18

40 SEQ ID NO: 18

SEQUENCE LENGTH: 18 base pairs

45 SEQUENCE TYPE: Nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

50 MOLECULE TYPE: other nucleic acid, synthesized DNA

55 SEQUENCE DESCRIPTION:

TGCAGACACA ACTACGGG

18

Claims

- 5 1. A process for detecting a nucleic acid comprising the steps of:
 (i) labelling a target nucleic acid to be detected;
 (ii) immobilizing single stranded nucleic acids specifically hybridizable with the target nucleic acid on a
 solid support to place said single stranded nucleic acid under such a condition that a strand complemen-
 tary to said single stranded nucleic acid is absent;
10 (iii) hybridizing said target nucleic acid labelled in step (i) with said single stranded nucleic acid immobi-
 lized in step (ii); and
 (iv) detecting, simultaneously with or after step (iii), said target nucleic acid through the utilization of a
 label present in said target nucleic acid.
- 15 2. A method of detecting a nucleic acid according to claim 1, wherein said target nucleic acid labelled in step
 (i) is a synthesized nucleic acid corresponding to the nucleic acid derived from a specimen or a synthesized
 nucleic acid complementary to the nucleic acid derived from a specimen.
- 20 3. A method of detecting a nucleic acid according to claim 1 or 2, wherein said single stranded nucleic acid
 immobilized in step (ii) contains a plurality of sequences specifically hybridizable with the target nucleic
 acid.
4. A method of detecting a nucleic acid according to claim 1 or 2, wherein said single stranded nucleic acid
 immobilized in step (ii) contains 5 to 200 sequences specifically hybridizable with the target nucleic acid.

25

30

35

40

45

50

55






FIG. 1



5'
CACCTGACTCCTG **A**GGAGAAGTCTGCCGTT β A
GTGGACTGAGGACT **T**CCTCTTCAGACGGCAA
3'

5'
CACCTGACTCCTG **T**GGAGAAGTCTGCCGTT β S
GTGGACTGAGGAC**A**CCTCTTCAGACGGCAA
3'

FIG. 3

**FIG. 4**




FIG. 5

| | | | |
|----------|---|-----|----|
| | 1 | 10 | 20 |
| DR1 | GGGGACACCCGACCACGTTCTTGTGGCACCTTAAGTTGAATGTCAATTCTCAATGGG | | |
| DR4 | -----GA---G---ACA---G-----C--- | | |
| DR4/Dw10 | -----GA---G---ACA---G-----C--- | | |
| DRw13 | -----A-----GA-T-CTC-C-C-G----- | | |
| | 30 | 40 | |
| DR1 | ACGGAGCGGGTCCGTTGCTGGAAAGATGCATCTATAACCAAGAGGAGTCGGTCCGCTTC | | |
| DR4 | -----C---C---A-T---C-----A----- | | |
| DR4/Dw10 | -----C---C---A-T---C-----A----- | | |
| DRw13 | -----C---C---A-T---C-----G---AA----- TACTTCTATACCAAGAGGA | | |
| | probe 1 | | |
| | 50 | 60 | |
| DR1 | GACAGCGACGTGGGGAGTACCGGGCGGTGACGGAGCTGGCGCGGCCCTGATGCCGAGTAC | | |
| DR4 | ----- | | |
| DR4/Dw10 | ----- | | |
| DRw13 | -----T----- | | |
| | 70 | 80 | |
| DR1 | TGGAACACCCAGAAGGACCTCTGGACCATGGGGGGGGGGGGGGGGTGACACCTACTGCAGA | | |
| DR4 | -----A----- | | |
| DR4/Dw10 | -----A-----AG-CGA----- | | |
| DRw13 | -----A-----AG-CGA----- GAAGACCGAGCGGGCGCG TGCAGA | | |
| | probe 2 | | |
| | 90 | 100 | |
| DR1 | CACAACTACGGGTTGGTGAGAGCTCACAGTGCAGCGCGAGTTGAGCCTAAGGTGACT | | |
| DR4 | -----CT-T---G----- | | |
| DR4/Dw13 | -----TG-----***** | | |
| DRw10 | -----TG-----CC-T----- | | |
| | CACAACTACGGG | | |
| | probe 3 | | |

--- indicates the same sequence as that of
the uppermost sequence.

* unknown

F I G . 6



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 30 5837

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | | | | | |
|--|---|---|--|-----------------|----------------------------------|----------|-----------|------------|---------------------|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int. Cl. 5) | | | | | | |
| X | EP-A-0 235 726 (MOLECULAR DIAGNOSTICS, INC.) * Page 3, line 37 - page 4, line 23; page 9, line 41 - page 10, line 15; page 18, line 5 - page 19, line 30; claim 1 * | 1-3 | C 12 Q 1/68 | | | | | | |
| Y | --- | 4 | | | | | | | |
| Y | GB-A-2 156 074 (ORION-YHTYMA OY) * Page 1, line 43 - page 4, line 24; figures 1-13; claims * | 4 | | | | | | | |
| A | WO-A-8 705 334 (ANGENICS, INC.) * Page 20, line 20 - page 21, line 12; page 23, line 21 - page 27, line 8 * | 1 | | | | | | | |
| P,X | EP-A-0 407 789 (CANON K.K.) * Page 4, line 20 - page 6, line 16; page 7, line 30 - page 10, line 15 * | 1,2 | | | | | | | |
| | | | TECHNICAL FIELDS SEARCHED (Int. Cl. 5) | | | | | | |
| | | | C 12 Q | | | | | | |
| <p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>15-10-1991</td> <td>LUZZATTO E.R.P.G.A.</td> </tr> </table> | | | | Place of search | Date of completion of the search | Examiner | THE HAGUE | 15-10-1991 | LUZZATTO E.R.P.G.A. |
| Place of search | Date of completion of the search | Examiner | | | | | | | |
| THE HAGUE | 15-10-1991 | LUZZATTO E.R.P.G.A. | | | | | | | |
| CATEGORY OF CITED DOCUMENTS | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | | | | | | |
| <small>FPO FORM 150103/2 (P0401)</small> | | | | | | | | | |